MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3324/haematol.2018.209932

Медицинская библиотека · Haematologica · 2019

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.

Bruna Riccardo, Benedetti Fabio, Boccomini Carola, Patti Caterina, Barbui Anna Maria, Pulsoni Alessandro, Musso Maurizio, Liberati Anna Marina, Gini Guido, Castellino Claudia, Rossini Fausto, Ciceri Fabio, Rota-Scalabrini Delia, Stelitano Caterina, Di Raimondo Francesco, Tucci Alessandra, Devizzi Liliana, Zoli Valerio, Zallio Francesco, Narni Franco, Dondi Alessandra, Parvis Guido, Semenzato Gianpietro, Lanza Francesco, Perrone Tommasina, Angrilli Francesco, Billio Atto, Gueli Angela, Mantoan Barbara, Rambaldi Alessandro, Gianni Alessandro Massimo, Corradini Paolo, Passera Roberto, Ladetto Marco, Tarella Corrado

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

A prospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (R-HDS) versus conventional chemotherapy with rituximab (CHOP-R) as first-line therapy in 134 high-risk follicular lymphoma patients aged <60 years. The study has been updated at the 13-year median follow up. As of February 2017, 88 (66%) patients were alive, with overall survival of 66.4% at 13 years, without a significant difference between R-HDS (64.5%) and CHOP-R (68.5%). To date, 46 patients have died, mainly because of disease progression (47.8% of all deaths), secondary malignancies (3 solid tumor, 9 myelodysplasia/acute leukemia; 26.1% of all deaths), and other toxicities (21.7% of all deaths). Complete remission was documented in 98 (73.1%) patients and associated with overall survival, with 13-year estimates of 77.0% and 36.8% for complete remission versus no-complete remission, respectively. Molecular remission was documented in 39 (65%) out of 60 evaluable patients and associated with improved survival. In multivariate analysis, complete remission achievement had the strongest effect on survival (P<0.001), along with younger age (P=0.002) and female sex (P=0.013). Overall, 50 patients (37.3%) survived with no disease recurrence (18 CHOP-R, 32 R-HDS). This follow up is the longest reported on follicular lymphoma treated upfront with rituximab-chemotherapy and demonstrates an unprecedented improvement in survival compared to the pre-rituximab era, regardless of the use of intensified or conventional treatment. Complete remission was the most important factor for prolonged survival and a high proportion of patients had prolonged survival in their first remission, raising the issue of curability in follicular lymphoma. (Registered at clinicaltrials.gov identifier: 00435955).

Для цитирования: Bruna Riccardo, Benedetti Fabio, Boccomini Carola, Patti Caterina, Barbui Anna Maria, Pulsoni Alessandro, Musso Maurizio, Liberati Anna Marina, Gini Guido, Castellino Claudia, Rossini Fausto, Ciceri Fabio, Rota-Scalabrini Delia, Stelitano Caterina, Di Raimondo Francesco, Tucci Alessandra, Devizzi Liliana, Zoli Valerio, Zallio Francesco, Narni Franco, Dondi Alessandra, Parvis Guido, Semenzato Gianpietro, Lanza Francesco, Perrone Tommasina, Angrilli Francesco, Billio Atto, Gueli Angela, Mantoan Barbara, Rambaldi Alessandro, Gianni Alessandro Massimo, Corradini Paolo, Passera Roberto, Ladetto Marco, Tarella Corrado. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.. Haematologica. 2019. DOI: 10.3324/haematol.2018.209932.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.